AC
GENE

Armistice Capital’s Genetic Technologies Ltd. GENE Stock Holding History

Armistice Capital’s Portfolio GENE Stock Details GENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-140,000
Closed -$210K – 328
2024
Q2 		$210K Buy
+140,000
New +$315K ﹤0.01% 210

Other funds holding GENE

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
ATS
Ashton Thomas Securities Rochester, New York $797M AUM 18.33% 1-Year Est. Return

Armistice Capital's GENE Position: Q3 2024 in Review

Armistice Capital sold out of Genetic Technologies Ltd. (GENE) in Q3 2024, closing a stake of 140,000 shares — an estimated $210K sold.

Armistice Capital first reported a position in GENE in Q2 2024 and held it in 1 quarter. The position peaked at $210K in Q2 2024. 10 funds tracked by Wall St. Rank hold GENE as of Q3 2024.

  • Armistice Capital reported no remaining Genetic Technologies Ltd. position as of Q3 2024 after selling out during the quarter.
  • Armistice Capital sold 140,000 Genetic Technologies Ltd. shares in Q3 2024, an estimated $210K.
  • Armistice Capital first reported a position in Genetic Technologies Ltd. in Q2 2024 and held it in 1 quarter.
  • Armistice Capital's Genetic Technologies Ltd. position peaked at $210K in Q2 2024.
  • 10 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q3 2024.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.